MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 

2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions
View by Date

Thursday, June 8, 2017

1:15pm-2:45pm
Istradefylline and Preladenant as adjuvant therapies for Patients with Parkinson’s disease

A. Negida, Z. Hassan, H. Ahmed, O. Hassan, A. Elsherbiny, S. Azzam, O. Osama, Y. Ibrahim (Zagazig, El-Sharkia, Egypt)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Exhibit Hall C
1:15pm-2:45pm
Istradefylline for daytime sleepiness and sleep disturbances in patients with Parkinson’s disease: an open-label, 3-month study

K. Suzuki, M. Miyamoto, T. Miyamoto, T. Uchiyama, Y. Watanabe, T. Kadowaki, K. Hirata (Mibu, Japan)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Exhibit Hall C
1:15pm-2:45pm
Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.

K. Ohta, Y. Kujuro, T. Osada (Tokyo, Japan)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Exhibit Hall C
1:15pm-2:45pm
Levodopa effect and motor function in late stage Parkinson’s disease

K. Rosqvist, P. Odin, M. Horne, P. Hagell, S. Iwarsson, M. Nilsson (Lund, Sweden)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Exhibit Hall C
1:15pm-2:45pm
Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.

N. Malek, M. Lawton, K. Grosset, N. Bajaj, R. Barker, Y. Ben-Shlomo, D. Burn, T. Foltynie, J. Hardy, H. Morris, N. Williams, N. Wood, D. Grosset (Ipswich, United Kingdom)

Clinical Trials and Therapy in Movement Disorders  ·  Exhibit Hall C
1:15pm-2:45pm
Levodopa/carbidopa Intestinal Gel Can Improve Both Motor and Non-Motor Experiences of Daily Living in Parkinson’s Disease: An Open-Label Study

N. Kovacs, A. Juhász, Z. Aschermann, P. Ács, J. Janszky, M. Kovács, A. Makkos, M. Harmat, D. Tényi, K. Katádi, S. Komoly, A. Takáts, A. Tóth, H. Nagy, P. Klivényi, G. Dibó, L. Dézsi, D. Zádori, Á. Annus, L. Vécsei, L. Varannai (Pécs, Hungary)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Exhibit Hall C
1:15pm-2:45pm
Link between striatal dopamine uptake and cortical dysconnectivity in Parkinson’s disease

A. Greuel, M. Tahmasian, F. Schwartz, S. Aschenberg, F. Maier, L. Timmermann, A. Drzezga, M. Tittgemeyer, C. Eggers (Cologne, Germany)

Parkinson's Disease: Neuroimaging And Neurophysiology  ·  Exhibit Hall C
1:15pm-2:45pm
Long-Term Dopamine Transporter Imaging and Clinical Effects of the Mixed-Lineage Kinase Inhibitor CEP-1347 in the PRECEPT Parkinson Trial

I. Shoulson, S.E. Eberly, D. Oakes, A. Lang, M. Schwarzschild, C. Tanner, J. Seibyl, K. Marek (Washington, DC, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Exhibit Hall C
1:15pm-2:45pm
Long-term effect of botulinum toxin injection in the external oblique muscle to treat camptocormia in three patients with Parkinson’s disease.

H. Todo (Sanda, Japan)

Clinical Trials and Therapy in Movement Disorders  ·  Exhibit Hall C
1:15pm-2:45pm
Longitudinal comparison of 11C-PE2I and 18F-DOPA PET for assessing severity and rate of disease progression in patients with Parkinson’s disease

W. Li, N. Lao-Kaim, A.-A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R. Barker, P. Piccini (London, United Kingdom)

Parkinson's Disease: Neuroimaging And Neurophysiology  ·  Exhibit Hall C